WO1999056701A1 - Antibiotic/medicated gutta percha point - Google Patents

Antibiotic/medicated gutta percha point Download PDF

Info

Publication number
WO1999056701A1
WO1999056701A1 PCT/US1998/009168 US9809168W WO9956701A1 WO 1999056701 A1 WO1999056701 A1 WO 1999056701A1 US 9809168 W US9809168 W US 9809168W WO 9956701 A1 WO9956701 A1 WO 9956701A1
Authority
WO
WIPO (PCT)
Prior art keywords
gutta percha
tetracycline
iodoform
root canal
medicated
Prior art date
Application number
PCT/US1998/009168
Other languages
French (fr)
Inventor
Howard Martin
Original Assignee
Howard Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Howard Martin filed Critical Howard Martin
Priority to PCT/US1998/009168 priority Critical patent/WO1999056701A1/en
Priority to US09/674,636 priority patent/US6602516B1/en
Publication of WO1999056701A1 publication Critical patent/WO1999056701A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/60Preparations for dentistry comprising organic or organo-metallic additives
    • A61K6/69Medicaments

Definitions

  • the present invention relates to antibacterial gutta percha for obturation of root canals and, more particularly, to an improved gutta percha point comprising tetracycline and/or iodoform and method for application of the same that yields a broader spectrum of effectiveness based upon the clinical symptomatology in combating the bacterial contamination of leakage and reinfection.
  • the method for application allows the dentist to chose the properly medicated gutta percha point for the individual case.
  • the aim of endodontic treatment is the elimination of infection from the root canal and the prevention of reinfection within the root canal.
  • Bacteria have long been recognized as the primary etiologic agent of reinfection within the root canal. Proper obturation of the root canal space is a key to this success.
  • Washington University study nearly 60% of the failures studied occurred because of canal leakage. Salivary fluid, apical fluids, and leakage infiltration due to open lateral canals because of periodontal disease, all contribute to leakage failure and subsequent reinfection of the root canal.
  • Loma Linda University (Torabinejad et al., J. Endo 1990,16:12,566) has also shown that a significant problem in leakage has been through the coronal aspect of the root canal due to delay in placing a permanent restoration, breaking down of the temporary seal, partial fractures or a poorly placed permanent restoration.
  • Over 50% of the root canals were contaminated within 19 days with Streptococcus epidermidis and Proteus vulgaris.
  • University of Iowa's Swanson and Madison (J. Endo, 1987 13:56) found, in their studies that in 82% of the cases, the entire root length was penetrated by bacteria, showing that traditional gutta percha was an inadequate seal.
  • Bacteria are also found to have penetrated the dentinal tubules during original infections and cannot be totally eliminated via biomechanical treatment procedures.
  • Iodoform has been shown to be ineffective against tested aerobes such as Streptococcus mutans, Streptococcus sanguis,
  • Escherchi coli Staphylococcus aureus, and the facultative anaerobe, Enterococci faecium, Actinomyces, Lactobacillus, Prevotella intermedius.
  • Figure 1 indicates that the iodoform/gutta percha of Martin's previous formulation will not always be effective against all types of organisms but is effective against facultative gram - and gram + rods and cocci as well as obligate anaerobes. This shows that iodoform gutta percha is more effective against a longstanding infection of the root canal and against organisms present within the oral microbiota that have reduced oxygen potential. However, it is not as effective against an oral salivary leakage contamination as determined by the previous leakage and bacterial investigations.
  • the above-described and other objects are accomplished by providing an improved gutta percha point comprising tetracycline and/or iodoform and method for application of the same that yields a broader spectrum of effectiveness based upon the clinical symptomatology in combating the bacterial contamination of leakage and reinfection.
  • a method of preparation of a compule and delivery by a cannula is also disclosed that allows the dentist to select the properly medicated gutta percha point for the individual case.
  • FIG. 1 is a table illustrating the results from a study at Naval Dental School, Bethesda, Maryland, the iodoform/gutta percha disclosed in U.S. Patent No. 5,648,403, issued July 15,1997. The results show that while iodoform 10% in gutta percha has antibacterial properties superior to traditional gutta percha, the combination will not always be effective against all types of organisms.
  • FIG. 2 is a table showing an in vitro study accomplished with tetracycline impregnated gutta percha points showing antimicrobial activity against a variety of specimens in an agar medium.
  • Gutta percha is a high molecular weight polymer trans polyiosprene. If it is heated above 65° C it becomes amorphous. It is cooled at 0.5° C per hour and will slowly recrystallize in the beta form which is the form of dental gutta percha usage. It is in the complex alpha and beta form that the dental gutta percha points are shaped. The gutta percha is amorphous when the zinc oxide, iodoform, tetracycline, dye, wax/resin are added. The baseplate gutta percha, a flat segment, is then cut into strips and either hand rolled or mechanically rolled into the predetermined gutta percha point sizes.
  • the antimicrobial chemicals, iodoform or tetracycline, that are utilized in the gutta percha point are incorporated into the form by a special warming process so as to be evenly distributed throughout the medicated gutta percha point.
  • the tetracycline hydrochloride salt is the proper choice for incorporation into the gutta percha as is the other tetracycline family of products in the chloride salt the choice also. This is also processed to be 99.95%) pure prior to insertion. Compression of the material is a factor and the material is mortared into the zinc oxide/gutta percha while still warm. The gutta percha, zinc oxide and antimicrobials, wax/resin must be
  • tetracycline The selection of tetracycline is predicated upon studies done that show that tetracycline will bind into bone and dentin within the root canal and will have little or no allergic reactions.
  • the Boston Collaborative Drug Surveillance Program determined that tetracycline caused no allergic reactions in more than 1,000 patients.
  • the tetracyclines are broad spectrum antibiotics and are effective against a wide variety of Gram positive and Gram negative organisms.
  • FIG. 2 The in vitro study is shown in FIG. 2 was accomplished with tetracycline impregnated gutta percha points showing antimicrobial activity against a variety of specimens in an agar medium.
  • the impregnated gutta percha produced significant zones of inhibition indicative of active tetracycline being leached from within the gutta percha point.
  • the untreated gutta percha displayed no inhibition. All tetracyclines appear to have essentially the same potency against the same organisms. Bacterial resistance against tetracycline develops slowly and has not been a significant problem. The important fact is that tetracyclines can become incorporated into calcified structures. This enables the tetracycline to leach out when contamination leakage occurs within the root canal.
  • Tetracycline will become incorporated within the dentinal tubules where bacteria are and will inhibit the lyophilized bacteria thereby not allowing these bacteria to regenerate and cause canal reinfection.
  • the tetracyline will also destroy and inhibit the bacteria that penetrate along the surface of the gutta percha points that have become contaminated due to apical, lateral or coronal microleakage after obturation.
  • Tetracycline is stable in an acid environment thereby making it effective in the inflamed area of the root canal periapex. Inflammation is an acidic environment that will neutralize most alkaline type antimicrobials.
  • the hydrochloride salt of tetracycline is the form utilized. Tetracycline has a higher blood level concentration than others in the tetracycline family except for the doxycycline form.
  • tetracycline can form a stable chelate complex with metallic ions such as calcium and magnesium thereby allowing the attachment to the dentinal wall within the root canal along which the leakage and contamination occurs.
  • the tetracycline is released in similar leaching fashion to iodoform impregnated gutta percha points.
  • Tissue fluid or salivary contamination causes the tetracycline, or iodoform, or the combination of the two antimicrobials to diffuse from the gutta percha points into the external medium, the contaminated tissue fluid within the canal.
  • Olsvik et al. J Clin.
  • the proper method of application of the optimum gutta percha point (inclusive of tetracycline and/or iodoform) according to the present invention therefore calls for the administering dentist to evaluate the clinical symptoms and radiographs to determine which medicated form of gutta percha should be utilized for the obturation technique.
  • the added advantage of tetracycline being able to coalesce within the canal wall is a distinct advantage for long standing root canal infections that would have bacterial penetration within the dentinal tubules.
  • iodoform gutta percha would be better for relative short term infected cases. In the case of swelling and purulence, a combination point of iodoform/tetracycline gutta percha would be the optimum choice.
  • the optimum gutta percha point (inclusive of tetracycline and/or iodoform) according to the present invention may then be applied by the lateral condensation technique. This is a compression of solid gutta percha cones together and adaptation to the canal walls.
  • the proper gutta percha formulation for tetracycline and/or iodoform according to the present invention is as shown below:
  • the preferred amounts of constituents as described above may vary by approximately 10% without significantly compromising effectiveness.
  • iodoform gutta percha iodoform/tetracycline gutta percha
  • tetracycline gutta percha is in the form of a heated compule with a pressure plunger delivering the thermo-softened material through a cannula into the prepared root canal system.
  • the iodoform gutta percha, tetracycline gutta percha, iodoforai/tetracycline gutta percha is formed into a heat labile amorphous mass and is placed within a compule that when heated will be able to be expressed through a cannula into the root canal system as a back filling procedure technique.
  • alpha phase gutta percha is impregnated with the iodoform, tetracycline or combination iodoform/tetracycline per the formulations described herein.
  • the medicated gutta percha forms are milled under advancing heat to thin the viscosity. Approximately 10-15 minutes are required to fully plasticize the medicated gutta percha within the compule heater.
  • the amorphous form is be sufficiently milled to plasticize at that temperature which takes longer and slower to achieve than the usual method described for normal incorporation of the aforementioned antimicrobials. This slower, longer process develops a lower melting point in the gutta percha, thereby enabling the flow phase when it is gently heated prior to the filling extrusion technique.
  • the amorphous form is then placed in its amorphous state within a pre existing plastic compule. These compules are available from several dental manufacturers and have been utilized for various light cured restorative resin materials. These compules have a cannula attached for expressing the antibiotic or medicated gutta percha into the canal.
  • the compules are heated by various conventional devices, thereby softening and thermoplasticizing the antiobiotic or medicated gutta percha. Any heat source that will reach 70° C is to be utilized to thermoplasticize the gutta percha within the compule for dispensing, but the temperature of the heating device must not go over 175 degrees F as the tetracycline or iodoform would be altered. It takes several minutes of heating the compule to enable the flowability so that proper extrusion of the antibiotic/medicated gutta percha will occur. Conventional compule syringes or compule guns are available for utilization as the pressure force for the extrusion phase.
  • UltrafilTM by Hygenic Corp has a system that uses a disposable cannula which can be heated in an oven to 70° C. The cannula is then placed in a modified ligamental syringe for injecting into the root canal.
  • the cannula gauge must be no larger than 22 but preferably 25.
  • the distinguishing factor is the new medicated forms of the gutta percha to be utilized in a heated compule so that the gutta percha softens and under pressure from the mechanical gun/syringe will flow out through the cannula into the root canal to obturate narrow areas, lateral canals, in the root canal system based upon its improved rheology.
  • This method can also be used in a backfill system of the canal after a master gutta percha cone has been fitted.
  • the tetracycline gutta percha will work against oral contamination, periodontal contamination and aerobic and facultative anaerobic organisms while not as effective against long standing infection.
  • the combination of tetracycline/iodoform gutta percha is the most effective against a wide variety of gram positive and negative organisms as well as aerobic, facultative and obligate anaerobes.
  • Iodoform gutta percha is effective against a longstanding infection of the root canal and against organisms present within the oral microbiota that have reduced oxygen potential. However, it is not as effective against an oral salivary leakage contamination as determined by the previous leakage and bacterial investigations. There would be a significant advantage to providing an alternative and combination gutta percha point and method for selection and application that has a broader spectrum of effectiveness based upon the clinical symptomatology, to thereby combat the bacterial contamination of leakage and reinfection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dental Preparations (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The ability to incorporate iodoform, tetracycline and a combination of iodoform/tetracycline into root canal gutta percha points is described. The iodoform, tetracycline and iodoform/tetracycline combination are bound within the gutta percha points. They act as a reservoir of antimicrobial that is capable of diffusing onto the surface of the gutta percha thereby inhibiting the colonization of bacteria on the gutta percha points and within the root canal system. Tetracycline is capable of coalescing within the dentinal tubules to inhibit long term microbial growth. These medicated gutta percha points are site specific, surface acting antimicrobial gutta percha points. A method of the usage and delivery of amorphous form iodoform gutta percha, iodoform/tetracycline gutta percha, or tetracycline gutta percha within a heated compule with a pressure plunger by delivering the thermo-softened heat labile amorphous form via a pressure extrusion system through a cannula into the prepared root canal system.

Description

ANTIBIOTIC/MEDICATED GUTTA PERCHA POINT
Technical Field The present invention relates to antibacterial gutta percha for obturation of root canals and, more particularly, to an improved gutta percha point comprising tetracycline and/or iodoform and method for application of the same that yields a broader spectrum of effectiveness based upon the clinical symptomatology in combating the bacterial contamination of leakage and reinfection. The method for application allows the dentist to chose the properly medicated gutta percha point for the individual case.
Background Art
The aim of endodontic treatment is the elimination of infection from the root canal and the prevention of reinfection within the root canal. Bacteria have long been recognized as the primary etiologic agent of reinfection within the root canal. Proper obturation of the root canal space is a key to this success. According to the Washington University study nearly 60% of the failures studied occurred because of canal leakage. Salivary fluid, apical fluids, and leakage infiltration due to open lateral canals because of periodontal disease, all contribute to leakage failure and subsequent reinfection of the root canal.
Complete obturation of the root canal is impossible via the universally accepted solid core filling material gutta percha. The usual method of obturation with gutta percha is the lateral condensation technique. This is a compression of the solid gutta percha cones together and adaptation to the canal walls. Numerous studies show leakage alongside the gutta percha cones due to the mere lamination of the gutta percha cones rather than developing a homogenous mass. Even the warm vertical/lateral condensation technique will not give a complete adaptation to the canal walls as shown by several leakage studies, all of which require root canal sealer to attempt to fill in the remairiing voids.
Loma Linda University (Torabinejad et al., J. Endo 1990,16:12,566) has also shown that a significant problem in leakage has been through the coronal aspect of the root canal due to delay in placing a permanent restoration, breaking down of the temporary seal, partial fractures or a poorly placed permanent restoration. Over 50% of the root canals were contaminated within 19 days with Streptococcus epidermidis and Proteus vulgaris. University of Iowa's Swanson and Madison (J. Endo, 1987 13:56) found, in their studies that in 82% of the cases, the entire root length was penetrated by bacteria, showing that traditional gutta percha was an inadequate seal.
An attendant problem within the root canal, is the polymicrobial aspect of the contamination. In a combined study, the University of Zurich and University of Umea, Sweden (Nair et al, J. Endo, 1990,16:580), showed that multiple bacterial species and two types of yeasts were found within the canals.
Fabricius' group extensive studies (Scand. J. Dent Res, 90:134,1982, Scand J. Dent Res, 1982,90: preprint, Scand J. Dent Res, 1982,90: preprint, Scand J Dent Res, 1981, B9:475) at University of Gothenburg, Sweden demonstrated that mixed infections of various bacterial strains were commonplace. His group found that anaerobic strains, especially Bacteroides species were present in longer standing infections and that aerobic or facultative anaerobic bacteria were more common in incipient or shorter to mid term infections.
In the apical region of the root canal, Fabricius found that the fastidious slow growing obligate anaerobic bacterial strains outnumbered the facultative strains.
Therefore, bacteria after closure, activated due to leakage by the inadequate seal of gutta percha, will after a time period multiply and reinfect the root canal as they require little or no oxygen to survive and replicate.
Bacteria are also found to have penetrated the dentinal tubules during original infections and cannot be totally eliminated via biomechanical treatment procedures.
These lyophilized bacteria will also become active during the leakage phase contributing to reinfection. The bacteria are of both types of Gram strain being positive
- 2 and negative. However, Gram negative predominates within the canal and both cocci and rods of each type are found. The longer-standing the infection, the more Gram negative rods are found.
The obligate anaerobic portion of root canal infection has been linked to the acute exacerbation or flare up. This is characterized by swelling, pus, pain and bone destruction. This has been corroborated by the benchmark bacteroidies study (J. Endo 15:13,1989) done by Sunqvist at the University of Umea, Sweden. This knowledge has been developed with the advent of the ability now to culture obligate anaerobic Gram negative organisms, These were previously undetected due to lack of this capability in prior bacteriologic studies. The dentist can now deteπnine, based upon symptomology, bacteriologic studies statistics, and etiology, the most likely type of bacteria present. The dentist then can utilize the correct pharmacologic obturation materials for treatment and preservation of the root canal integrity.
Eguchi et al at the endodontic research clinic, US Army, Ft. Campbell, Ky. (J. Endo, 11 : 166, 1985) showed that no matter what technique was used with gutta percha for obturation, lateral, vertical heat, mechanical or chemical dip, the range of obturation sealing was 77-95%. This allows sufficient space for the breakdown and reinfection due to leakage contamination to occur, as well as failure due to poor fills, and failure due to inadequate cleaning and disinfection. Gutta percha is the obturation material of choice. Its antibacterial properties are not significant in its traditional form. The present inventor has previously disclosed in U.S. Patent No. 5,648,403, issued July 15, 1997, that iodoform 10% in gutta percha has antibacterial properties superior to traditional gutta percha.
However, upon further testing, Iodoform has been shown to be ineffective against tested aerobes such as Streptococcus mutans, Streptococcus sanguis,
Escherchi coli, Staphylococcus aureus, and the facultative anaerobe, Enterococci faecium, Actinomyces, Lactobacillus, Prevotella intermedius. This study was
- 3 accomplished at the Naval Dental School, Bethesda, Maryland, and the results are as shown in Figure 1. Figure 1 indicates that the iodoform/gutta percha of Martin's previous formulation will not always be effective against all types of organisms but is effective against facultative gram - and gram + rods and cocci as well as obligate anaerobes. This shows that iodoform gutta percha is more effective against a longstanding infection of the root canal and against organisms present within the oral microbiota that have reduced oxygen potential. However, it is not as effective against an oral salivary leakage contamination as determined by the previous leakage and bacterial investigations.
It would be significantly advantageous to provide an alternative and combination gutta percha point and method for selection and application that has a broader spectrum of effectiveness based upon the clinical symptomatology, to thereby combat the bacterial contamination of leakage and reinfection.
Disclosure of Invention According to the present invention, the above-described and other objects are accomplished by providing an improved gutta percha point comprising tetracycline and/or iodoform and method for application of the same that yields a broader spectrum of effectiveness based upon the clinical symptomatology in combating the bacterial contamination of leakage and reinfection. A method of preparation of a compule and delivery by a cannula is also disclosed that allows the dentist to select the properly medicated gutta percha point for the individual case.
Brief Description of Drawings These and other advantages of the disclosed invention will become apparent from a reading of the following description when read in conjunction with the accompanying drawings in which:
FIG. 1 is a table illustrating the results from a study at Naval Dental School, Bethesda, Maryland, the iodoform/gutta percha disclosed in U.S. Patent No. 5,648,403, issued July 15,1997. The results show that while iodoform 10% in gutta percha has antibacterial properties superior to traditional gutta percha, the combination will not always be effective against all types of organisms.
FIG. 2 is a table showing an in vitro study accomplished with tetracycline impregnated gutta percha points showing antimicrobial activity against a variety of specimens in an agar medium.
Best Mode(s) for Carrying Out the Invention Gutta percha is a high molecular weight polymer trans polyiosprene. If it is heated above 65° C it becomes amorphous. It is cooled at 0.5° C per hour and will slowly recrystallize in the beta form which is the form of dental gutta percha usage. It is in the complex alpha and beta form that the dental gutta percha points are shaped. The gutta percha is amorphous when the zinc oxide, iodoform, tetracycline, dye, wax/resin are added. The baseplate gutta percha, a flat segment, is then cut into strips and either hand rolled or mechanically rolled into the predetermined gutta percha point sizes.
The antimicrobial chemicals, iodoform or tetracycline, that are utilized in the gutta percha point are incorporated into the form by a special warming process so as to be evenly distributed throughout the medicated gutta percha point. Iodoform of
99.5%o purity must be used. All impurities are removed in creating the triodomethane. The tetracycline hydrochloride salt is the proper choice for incorporation into the gutta percha as is the other tetracycline family of products in the chloride salt the choice also. This is also processed to be 99.95%) pure prior to insertion. Compression of the material is a factor and the material is mortared into the zinc oxide/gutta percha while still warm. The gutta percha, zinc oxide and antimicrobials, wax/resin must be
5 - thoroughly milled to insure complete dispersion throughout the gutta percha point.
It is the intention of the present application to improve upon the description of proper processing iodoform and the usage of iodoform in gutta percha points for specific organisms, the addition of the antibiotic tetracycline for other susceptible organisms, as well as creating a combination medicated gutta percha point for greater antibacterial spectrum usage.
The selection of tetracycline is predicated upon studies done that show that tetracycline will bind into bone and dentin within the root canal and will have little or no allergic reactions. The Boston Collaborative Drug Surveillance Program determined that tetracycline caused no allergic reactions in more than 1,000 patients. The tetracyclines are broad spectrum antibiotics and are effective against a wide variety of Gram positive and Gram negative organisms.
The in vitro study is shown in FIG. 2 was accomplished with tetracycline impregnated gutta percha points showing antimicrobial activity against a variety of specimens in an agar medium. The impregnated gutta percha produced significant zones of inhibition indicative of active tetracycline being leached from within the gutta percha point. The untreated gutta percha displayed no inhibition. All tetracyclines appear to have essentially the same potency against the same organisms. Bacterial resistance against tetracycline develops slowly and has not been a significant problem. The important fact is that tetracyclines can become incorporated into calcified structures. This enables the tetracycline to leach out when contamination leakage occurs within the root canal. Tetracycline will become incorporated within the dentinal tubules where bacteria are and will inhibit the lyophilized bacteria thereby not allowing these bacteria to regenerate and cause canal reinfection. The tetracyline will also destroy and inhibit the bacteria that penetrate along the surface of the gutta percha points that have become contaminated due to apical, lateral or coronal microleakage after obturation.
Tetracycline is stable in an acid environment thereby making it effective in the inflamed area of the root canal periapex. Inflammation is an acidic environment that will neutralize most alkaline type antimicrobials. A distinct advantage for the tetracyclines. The hydrochloride salt of tetracycline is the form utilized. Tetracycline has a higher blood level concentration than others in the tetracycline family except for the doxycycline form. As noted, tetracycline can form a stable chelate complex with metallic ions such as calcium and magnesium thereby allowing the attachment to the dentinal wall within the root canal along which the leakage and contamination occurs.
The tetracycline is released in similar leaching fashion to iodoform impregnated gutta percha points. Tissue fluid or salivary contamination causes the tetracycline, or iodoform, or the combination of the two antimicrobials to diffuse from the gutta percha points into the external medium, the contaminated tissue fluid within the canal. It is the ability of the tetracycline or iodoform to depress or suppress bacterial growth that results in maintaining the integrity of the root canal obturation. This has been shown to be accomplished in more open cases such as periodontal pocket disease by Tonetti et al (Int. J. Perio Rest Dent 14:421,1994). However, Olsvik et al. (J Clin. Perio. 22:391, 1995) has shown that anaerobic gram negative rods and Streptococcus spp. was resistant to tetracycline with an overall resistant rate of 23%>. This demonstrates that tetracycline is not an all inclusive microbial inhibitor. It is therefore necessary to selectively combine the tetracycline with the iodoform to expand the spectrum of bacteriostasis or bacteriocidal effects within the failing root canal gutta percha.
The proper method of application of the optimum gutta percha point (inclusive of tetracycline and/or iodoform) according to the present invention therefore calls for the administering dentist to evaluate the clinical symptoms and radiographs to determine which medicated form of gutta percha should be utilized for the obturation technique. The added advantage of tetracycline being able to coalesce within the canal wall is a distinct advantage for long standing root canal infections that would have bacterial penetration within the dentinal tubules. On the other hand, iodoform gutta percha would be better for relative short term infected cases. In the case of swelling and purulence, a combination point of iodoform/tetracycline gutta percha would be the optimum choice.
In this latter case where a combination antimicrobial iodoform/tetracycline gutta percha point is selected, barium sulfate is removed completely, as the iodoform acts as the radioopacifier as well as an antimicrobial.
The optimum gutta percha point (inclusive of tetracycline and/or iodoform) according to the present invention may then be applied by the lateral condensation technique. This is a compression of solid gutta percha cones together and adaptation to the canal walls. The proper gutta percha formulation for tetracycline and/or iodoform according to the present invention is as shown below:
Tetracycline Gutta Percha point:
Gutta Percha - 20%
Zinc Oxide - 57% Barium Sulfate - 10%
Beeswax - 3%
Tetracycline HC1 - 10%
Combined Antimicrobial Gutta Percha point:
Gutta Percha - 20% Zinc Oxide - 57%
Triiodomethane (Iodoform) 10%
Tetracycline HC1 - 10%
Beeswax - 3%
The preferred amounts of constituents as described above may vary by approximately 10% without significantly compromising effectiveness.
Another format of the usage and delivery of the above-described iodoform gutta percha, iodoform/tetracycline gutta percha, or tetracycline gutta percha is in the form of a heated compule with a pressure plunger delivering the thermo-softened material through a cannula into the prepared root canal system. For this, the iodoform gutta percha, tetracycline gutta percha, iodoforai/tetracycline gutta percha is formed into a heat labile amorphous mass and is placed within a compule that when heated will be able to be expressed through a cannula into the root canal system as a back filling procedure technique. To prepare the amorphous form of the iodoform gutta percha, tetracycline gutta percha, or iodoform/tetracycline gutta percha, alpha phase gutta percha is impregnated with the iodoform, tetracycline or combination iodoform/tetracycline per the formulations described herein. The medicated gutta percha forms are milled under advancing heat to thin the viscosity. Approximately 10-15 minutes are required to fully plasticize the medicated gutta percha within the compule heater. The amorphous form is be sufficiently milled to plasticize at that temperature which takes longer and slower to achieve than the usual method described for normal incorporation of the aforementioned antimicrobials. This slower, longer process develops a lower melting point in the gutta percha, thereby enabling the flow phase when it is gently heated prior to the filling extrusion technique. The amorphous form is then placed in its amorphous state within a pre existing plastic compule. These compules are available from several dental manufacturers and have been utilized for various light cured restorative resin materials. These compules have a cannula attached for expressing the antibiotic or medicated gutta percha into the canal. The compules are heated by various conventional devices, thereby softening and thermoplasticizing the antiobiotic or medicated gutta percha. Any heat source that will reach 70° C is to be utilized to thermoplasticize the gutta percha within the compule for dispensing, but the temperature of the heating device must not go over 175 degrees F as the tetracycline or iodoform would be altered. It takes several minutes of heating the compule to enable the flowability so that proper extrusion of the antibiotic/medicated gutta percha will occur. Conventional compule syringes or compule guns are available for utilization as the pressure force for the extrusion phase. A commercially available V-shaped pistol grip holder compule gun/syringe as utilized routinely in restorative dentistry can be used as the dispensing source. Ultrafil™ by Hygenic Corp has a system that uses a disposable cannula which can be heated in an oven to 70° C. The cannula is then placed in a modified ligamental syringe for injecting into the root canal. For the iodoform gutta percha, iodoform/tetracycline gutta percha or tetracycline gutta percha of the present invention, the cannula gauge must be no larger than 22 but preferably 25.
Therefore, the distinguishing factor is the new medicated forms of the gutta percha to be utilized in a heated compule so that the gutta percha softens and under pressure from the mechanical gun/syringe will flow out through the cannula into the root canal to obturate narrow areas, lateral canals, in the root canal system based upon its improved rheology. This method can also be used in a backfill system of the canal after a master gutta percha cone has been fitted.
The above-described method of delivery of the medicated gutta percha will enable a rapid obturation of the middle and cervical portion of the root canal. What is of importance here is the fact of the site specificity and surface action of the iodoform and tetracycline effects as antimicrobials, the method of incorporation of the iodoform, tetracycline or iodoform/tetracycline into gutta percha and the processing of the same within the gutta percha point. As the studies have shown, iodoform gutta percha will work against certain aerobic bacteria, while it is most effective against obligate anaerobic and facultative anaerobic organisms of the long standing infections. The tetracycline gutta percha will work against oral contamination, periodontal contamination and aerobic and facultative anaerobic organisms while not as effective against long standing infection. The combination of tetracycline/iodoform gutta percha is the most effective against a wide variety of gram positive and negative organisms as well as aerobic, facultative and obligate anaerobes.
Obviously, many modifications may be made without departing from the spirit of the present invention. Accordingly, it will be appreciated by those skilled in the art
10 that within the scope of the appended claims, the invention may be practiced other than has been specifically described herein.
Industrial Applicability Iodoform gutta percha is effective against a longstanding infection of the root canal and against organisms present within the oral microbiota that have reduced oxygen potential. However, it is not as effective against an oral salivary leakage contamination as determined by the previous leakage and bacterial investigations. There would be a significant advantage to providing an alternative and combination gutta percha point and method for selection and application that has a broader spectrum of effectiveness based upon the clinical symptomatology, to thereby combat the bacterial contamination of leakage and reinfection. It would also be advantageous to provide an improved method for preparing and delivering the above-described iodoform gutta percha, iodoform/tetracycline gutta percha, or tetracycline gutta percha in the form of a heated compule through a cannula into the prepared root canal system.
11 -

Claims

Claims
1. An antimicrobial gutta percha point for use in root canal obturation comprising the following relative quantities of constituents:
Gutta Percha - 20%; Zinc Oxide - 57%; Truodomethane (iodoform) - 10%;
Tetracycline - 10%; and Beeswax - 3%; said relative quantities being variable within a range of +/- 10%.
2. The antimicrobial gutta percha point for use in root canal obturation according to claim 1, wherein said tetracycline further comprises at least one from among the group of HCl, Tetracycline phosphate complex, Doxycycline hyclate, Minocycline HCl, Oxytetracycline HCl, Chlortetracycline HCl, and Demethylchlortetracycline HCl.
3. A formula for a tetracycline medicated gutta percha point for use in root canal obturation consisting of the following constituents:
Gutta Percha - 20%; Zinc Oxide - 57%; Tetracycline HCl - 10%; Barium sulfate - 10%; Beeswax - 3%; said relative quantities being variable within a range of +/- 10%o.
4. A process to incorporate one from among the group consisting of truodomethane (iodoform) and tetracycline HCl into a gutta percha point comprising the steps of: making Gutta Percha amorpohous by melting above 65 C; cooling said Gutta Percha at 0.5 C per hour; combining zinc oxide, barium sulfate, beeswax, and one from among the group
- 12 - of iodoform and tetracycline by one of mixing compressing, or mortaring; milling the combination into a flat form, cutting into strips, and forming into a gutta percha point having a predetermined tapered shape.
5. A method for administering medicated gutta percha for use in root canal obturation, comprising the steps of: combining zinc oxide, barium sulfate, beeswax, and one from among the group of iodoform and tetracycline in an amorphous mass; placing said medicated amorphous mass within a preformed compule; heating said medicated amorphous mass within said compule; pressure-extruding said medicated amorphous mass from said compule through a cannula into the root canal.
- 13
PCT/US1998/009168 1998-05-05 1998-05-05 Antibiotic/medicated gutta percha point WO1999056701A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US1998/009168 WO1999056701A1 (en) 1998-05-05 1998-05-05 Antibiotic/medicated gutta percha point
US09/674,636 US6602516B1 (en) 1998-05-05 1998-05-05 Antibiotic/medicated gutta percha point

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/009168 WO1999056701A1 (en) 1998-05-05 1998-05-05 Antibiotic/medicated gutta percha point

Publications (1)

Publication Number Publication Date
WO1999056701A1 true WO1999056701A1 (en) 1999-11-11

Family

ID=22266988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/009168 WO1999056701A1 (en) 1998-05-05 1998-05-05 Antibiotic/medicated gutta percha point

Country Status (1)

Country Link
WO (1) WO1999056701A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951895A2 (en) * 1998-04-22 1999-10-27 ROEKO GmbH + Co. Dentalerzeugnisse Composition for filling root canals of teeth
EP2914233A4 (en) * 2012-11-02 2016-05-25 Ozdent Pty Ltd Dental compositions
CN106420620A (en) * 2016-09-28 2017-02-22 重庆大学 Aureomycin mesilate soluble powder and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648403A (en) * 1995-10-16 1997-07-15 Martin; Howard Antimicrobial gutta percha cone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648403A (en) * 1995-10-16 1997-07-15 Martin; Howard Antimicrobial gutta percha cone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABBOTT P. V., HUME W. R., PEARMAN J. W.: "ANTIBIOTICS AND ENDODONTICS.", AUSTRALIAN DENTAL JOURNAL, AUSTRALIAN DENTAL ASSOCIATION, SYDNEY, AU, vol. 35., no. 01., 1 February 1990 (1990-02-01), AU, pages 50 - 60., XP000866517, ISSN: 0045-0421 *
SEOW W. K.: "THE EFFECTS OF DYADIC COMBINATIONS OF ENDODONTIC MEDICAMENTS ON MICROBIAL GROWTH INHIBITION.", PEDIATRIC DENTISTRY., XX, US, vol. 12., no. 05., 1 September 1990 (1990-09-01), US, pages 292 - 297., XP000869631, ISSN: 0164-1263 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951895A2 (en) * 1998-04-22 1999-10-27 ROEKO GmbH + Co. Dentalerzeugnisse Composition for filling root canals of teeth
EP0951895A3 (en) * 1998-04-22 2004-01-02 ROEKO GmbH + Co. Dentalerzeugnisse Composition for filling root canals of teeth
EP2914233A4 (en) * 2012-11-02 2016-05-25 Ozdent Pty Ltd Dental compositions
US9861646B2 (en) 2012-11-02 2018-01-09 Ozdent Pty Ltd Dental compositions
CN106420620A (en) * 2016-09-28 2017-02-22 重庆大学 Aureomycin mesilate soluble powder and preparation method thereof

Similar Documents

Publication Publication Date Title
Siqueira Jr et al. Intracanal medicaments: evaluation of the antibacterial effects of chlorhexidine, metronidazole, and calcium hydroxide associated with three vehicles
Mohammadi et al. A review on triple antibiotic paste as a suitable material used in regenerative endodontics
Shipper et al. Periapical inflammation after coronal microbial inoculation of dog roots filled with gutta-percha or resilon
Rajsheker et al. Obturating Materials Used for Pulpectomy in Primary Teeth-A Mini Review
Neelakantan et al. Bacteriology of deep carious lesions underneath amalgam restorations with different pulp-capping materials-an in vivo analysis
US6602516B1 (en) Antibiotic/medicated gutta percha point
Brännström et al. Materials techniques for lining composite resin restorations: a critical approach
WO1989010736A1 (en) Antibacterial dental materials
WO2008079149A1 (en) Dental antimicrobial formulations and methods of using the same
US9486393B2 (en) Single component tooth root sealer
Fathi et al. An in vitro comparison of bacterial leakage of three common restorative materials used as an intracoronal barrier
Park et al. Immature permanent teeth with apical periodontitis and abscess treated by regenerative endodontic treatment using calcium hydroxide and MTA: a report of two cases
WO1999056701A1 (en) Antibiotic/medicated gutta percha point
Neelakantan et al. An analysis of the antimicrobial activity of ten root canal sealers-a duration based in vitro evaluation
Brosco et al. Bacterial leakage in root canals obturated by different techniques. Part 1: microbiologic evaluation
Jindal et al. Comparative Evaluation of the Interappointment Pain by Using Different Intracanal Medicaments—An In Vivo Study
Madison et al. Medications and temporaries in endodontic treatment
Uyan et al. Comparative evaluation of postoperative pain intensity after single-visit and multiple-visit retreatment cases: a prospective randomized clinical trial
Halkai et al. Evaluation of antimicrobial action and push-out bond strength and compressive strength using mineral trioxide aggregate and triple antibiotic medicament combination as root-end filling material: A novel: in vitro: study
Valkov et al. Temporary filling materials in endodontics—a literature review
Manzoor et al. Obturating materials in pediatric dentistry: A review
Wu et al. Clinical and experimental observations on resinifying therapy
Tsao Endodontic treatment in China.
Sharma et al. Recent advancements in root canal sealers-An overview
Bayoumy et al. Clinical and Microbiological Evaluation of Calcium Silicate Versus Calcium Hydroxide in Two-step Indirect Pulp Treatment: A Randomized Clinical Trial

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09674636

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA